Oxford 7 February 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today the appointment of Bill Fleming as its Chief Financial Ofﬁcer. This appointment represents an important milestone for the company which aims to beneﬁt cancer patients through developing new and improved medicines.
Bill’s career spans over 25 years in a broad range of ﬁnance positions in the biotech arena. Holding a law degree from Cambridge University and as a qualiﬁed ACMA, Bill has accumulated international FD/CFO experience in small venture-backed companies and large blue chips.
Bill served as European Finance Director for Visible Genetics, a pioneering company in the ﬁeld of nucleic acid diagnostics, subsequently holding senior ﬁnance positions for Bayer Healthcare in Europe and the USA. Bill played a leading role in securing investment for Oxford University spinout Oxitec and in its successful acquisition by Intrexon Corporation.
“Celleron Therapeutics is at a signiﬁcant stage in its growth, with clinical trials in a variety of unmet cancer indications underway. We are delighted that Bill will be joining us, where he can apply his considerable ﬁnancial knowledge derived from healthcare and life sciences to help progress the Company’s clinical and commercial objectives.”
said CEO Professor Nick La Thangue.
Bill Fleming commented:
“It is a great pleasure to join Celleron Therapeutics. The Company has amassed a pipeline of innovative drugs in clinical trials. I look forward to applying my extensive experience and knowledge in generating commercial traction and ﬁnancial success.”
About Celleron Therapeutics
Celleron Therapeutics, based on the Oxford Science Park, UK, is a precision cancer medicine company focussed on developing a suite of novel drugs. It is a spin-out of Oxford University and has secured a number of exclusive license agreements with pharmaceutical companies, including Astra Zeneca. The Company has entered into a license with China-based Company Nuance. Celleron’s precision medicine approach is supported by a companion diagnostic biomarker platform, which allows new drugs to be tailored to responsive tumours. Celleron has two Phase 2 clinical assets: CXD101 is a novel dual mechanism HDAC inhibitor which has unique immuno-modulatory effects, and CXD201 represents a new type of topoisomerase inhibitor.